Search results
13 wrz 2012 · Lower extremity spasticity can limit ambulation, such as when an equinovarus foot prevents the foot flat position during the stance phase of gait, resulting in instability, and resulting in knee pain attributable to excessive recurvatum when ankle plantar flexor spasticity overwhelms.
- View EPUB
PK {ºªXoa«, mimetypeapplication/epub+zipPK {ºªX...
- PDF/Epub
PK ñ3 Woa«, mimetypeapplication/epub+zipPK ñ3 W...
- C. Collin
Background and Purpose—We sought to define an effective and...
- Intrathecal Baclofen for Spastic Hypertonia From Stroke
Methods— Stroke patients with >6 months of intractable...
- View PDF
stated,2,18 but it is widely acknowledged that treatment of...
- Monitoring Brain Repair in Stroke Using Advanced Magnetic Resonance Imaging
Thrombolysis and endovascular interventions have...
- View EPUB
The Botox Economic Spasticity Trial (BEST) aimed to treat patients in Europe and Canada with upper and/or lower limb post-stroke spasticity with onabotulinumtoxinA in a manner similar to clinical practice by using goal-oriented treatment (Goal Attainment Scaling).
20 paź 2024 · Botulinum toxin A (BoNT-A) has been in clinical use for treating post-stroke spasticity for approximately 30 years and is the accepted standard of care for focal post-stroke spasticity (1).
The authors screened independently the title and abstract of studies, identified through the literature for potential inclusion. For this study, BoNTA (Botox® or Dysport® or Xeomin®) was defined to include any clinical use, of any dosage or duration, for the treatment of adult post-stroke lower limb spasticity (PSLLS).
The results of the reviewed studies of BTX treatment in poststroke upper and lower limb spasticity suggest that BTX injections safely and effectively decrease muscle tone and increase range of motion.
11 maj 2019 · Botulinum Toxin A (BT) is an effective intervention for focal spasticity, but its use is currently restricted in many countries by their reimbursement system stating that the evidence for improvement in walking and quality of life (QOL) is not robust for treatment in the lower limb.
Botulinum toxin A (BoNT-A) has been in clinical use for treating post-stroke spasticity for approximately 30 years and is the accepted standard of care for focal post-stroke spasticity (1).
